Tirzepatide

The 40mg Tirzepatide research pen provides double the assayed content of the 20mg format. It carries the same dual GIP/GLP-1 agonist research profile — a synthetic 39-amino-acid peptide acylated with a C20 fatty diacid for albumin binding — at a higher total content for laboratories running extended concentration series, multi-arm comparator studies or longer-duration protocols from a single batch. Same purity specification, same independent COA verification, same metered-dose device.

Tirzepatide is a synthetic 39-amino-acid peptide engineered for balanced agonism at both the GIP and GLP-1 receptors, acylated with a C20 fatty diacid for albumin binding and extended half-life. Research describes complementary signalling through the two receptor populations: GLP-1 receptor activity affecting insulin secretion, glucagon suppression and satiety, and GIP receptor activity additionally implicated in adipose tissue metabolism and nutrient handling. The relative contribution of the GIP arm remains an active area of mechanistic debate in the published literature.

Clinical characterisation of Tirzepatide is extensive and the mechanistic literature is developing quickly. Head-to-head trial data exists against single-agonist GLP-1 compounds. Research has investigated metabolic endpoints including glycaemic control and body composition across large cohorts. The 40mg format is suited to extended protocols and dose-response series that benefit from a larger single-batch supply. Ongoing mechanistic debate continues into whether GIP receptor agonism or antagonism drives the compound's observed effects.

• 10 mg per application (one metered dose)
• 4 doses per pen (40 mg total)
• Pre-filled sterile solution — no reconstitution step required
• Replace cap after each application; store refrigerated between uses

Storage: Store refrigerated at 2–8 °C in the original sealed box. Do not freeze. Protect from light.

• For in-vitro laboratory and preclinical research only — not for human or animal administration
• Higher-concentration format for extended protocols and multi-arm dose-response studies
• Dual GIP / GLP-1 mechanism: controls for both receptor pathways required in endpoint-specific studies

• SURMOUNT-1 Phase 3 (NEJM 2022): nausea (20%), diarrhoea (17%), constipation (10%), vomiting (6%) — class effects, dose-dependent
• Decreased appetite, injection site reactions
• Gallbladder-related events in longer clinical trials

Effects listed are observations from published research literature and are not predictions for any specific use. All FAB Research products are for in-vitro laboratory research — not for human or animal administration.